Editorial
Statins are, by and far, the number one prescribed class of medication worldwide [1] . Their mechanism of action is by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme responsible for the production of cholesterol. They are effective in lowering low-density lipoprotein (LDL) cholesterol and have consistently shown to reduce the risk of cardiovascular events as well as overall mortality [1] .
The most common side effect associated with statins is skeletal muscle toxicity that includes pain without evidence of muscle degradation (myalgias), pain with evidence of muscle degradation (myopathy), and severe muscle damage with acute kidney injury (rhabdomyolysis) [2] . Controlled clinical trials have shown that statin-associated myalgia occurred in 1% to 5% of patients; however, in post-marketing observational cohorts, 11% to 29% of patients experienced statin-associated myalgia [3] .
Regarding this association between statins and skeletal muscle toxicity, an important pharmacogenetic marker to consider is the SLCO1B1 gene. The solute carrier organic anion transporter family member 1B1 (SLCO1B1) protein facilitates the hepatic uptake of statins [2] . The most significant variant associated with the SLCO1B1 gene, c.521T>C, leads to decreased transport function of SLCO1B1 that can reduce the clearance of statins. In turn, this could lead to a greater chance of skeletal muscle toxicity. A meta-analysis of nine case-control studies that included 4,442 patients showed that individuals with the variant C allele were significantly more likely to experience statin-related myopathy (TC + CC vs. TT: odds ratio=2.09; 95% CI=1.27-3.43) [4] . The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing recommendations regarding simvastatin and the activity of the SLCO1B1 enzyme ( 
